Drug details:
Molecular formula: C₁₈H₁₆N₄O₃S₂

Standard name: 11-(furan-2-ylmethyl)-10-[(5-oxo-1,2-dihydropyrazol-3-yl)methylsulfanyl]-7-thia-9,11-diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9-trien-12-one

Synonym:

11-(furan-2-ylmethyl)-10-[(5-oxo-1,2-dihydropyrazol-3-yl)methylsulfanyl]-7-thia-9,11-diazatricyclo[6.4.0.02,6]dodeca-1(8),2(6),9-trien-12-one

Curated SMILES: O=C1C2=C(N=C(SCC3=NNC(O)=C3)N1CC1=CC=CO1)SC1=C2CCC1

Evidence for compound's anti-virulence activity:

Acinetobacter
Related VFcategory: Biofilm
Target: Not determined
Drug effect: An ATP mimetic compound targeting bacterial kinases/ATP-utilizing enzymes to inhibit biofilm formation.
Max phase: Preclinical (in vitro)
Publication:
Koopman JA, et al., 2015. Inhibition of Salmonella enterica biofilm formation using small-molecule adenosine mimetics. Antimicrob Agents Chemother 59(1):76-84.

Salmonella
Related VFcategory: Biofilm
Target: GroEL;DeoD
Drug effect: Inhibits biofilm formation by shifting cells out of microcolonies and into the planktonic phase, or maintaining them in a planktonic phase.
Max phase: Preclinical (in vitro)
Publication:
Koopman JA, et al., 2015. Inhibition of Salmonella enterica biofilm formation using small-molecule adenosine mimetics. Antimicrob Agents Chemother 59(1):76-84.